Company news
Ascelia Pharma AB news in 2026
Ascelia Pharma AB's news releases, calls and decks from 2026, newest first.
Ascelia Pharma Announces Publication of Orviglance Clinical Study in Journal of Magnetic Resonance Imaging
September 24, 2026
Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA
September 10, 2026
Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026
August 17, 2026
Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base
July 15, 2026
Ascelia Pharma Provides Update on the Orviglance NDA
July 3, 2026
Ascelia Pharma Expands Orviglance IP Portfolio with New Patent Filing
June 30, 2026
Ascelia Pharma Carries Out a Directed Share Issue of SEK 20 Million
April 23, 2026
Notice of Annual General Meeting in Ascelia Pharma AB
March 30, 2026
Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026
March 27, 2026
Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company
January 21, 2026
Calls in 2026
Decks in 2026
- Q2 2026 Earnings Presentation
Earnings · 24 slides · Aug 20, 2026
- Q4 2025 Earnings Presentation
Earnings · 23 slides · Feb 5, 2026